Covid 19 Research using Clinical Trials (Home Page)
HP:0000646: AmblyopiaHPO
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (3)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug893 | DigiVis visual acuity app Wiki | 1.00 |
| drug376 | Baricitinib Wiki | 0.38 |
| drug2122 | Placebo Wiki | 0.05 |
Correlated MeSH Terms (3)
| Name (Synonyms) | Correlation | |
|---|---|---|
| D000550 | Amblyopia NIH | 1.00 |
| D014786 | Vision Disorders NIH | 0.71 |
| D015354 | Vision, Low NIH | 0.71 |
Correlated HPO Terms (2)
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0000505 | Visual impairment HPO | 0.71 |
| HP:0012047 | Hemeralopia HPO | 0.71 |
There is one clinical trial.
Clinical Trials
1 DigiVis: Validation of Self-testing Visual Acuity Web-based App to Aid Ophthalmic Telephone Consultations During Covid19 Lockdown and Subsequent Social Distancing Crisis
This trial aims to assess the accuracy and test-retest variability of a new digital app which enables community visual acuity testing without requirement of an trained examiner.
NCT04482387 Visual Impairment Amblyopia Suspect Device: DigiVis visual acuity app MeSH:Amblyopia Vision Disorders Vision, Low
HPO:Amblyopia Hemeralopia Metamorphopsia Visual impairment
Primary Outcomes
Description: Measurement bias in logMAR units between DigiVis testing and standard visual acuity testing score compared to
Measure: Comparison of visual acuity measurement using DigiVis testing and standard visual acuity testing Time: within 30 days
Description: Upper and lower levels of agreement measured in logMAR units
Measure: Levels of Agreement between DigiVis testing and standard visual acuity testing Time: within 30 days
Secondary Outcomes
Description: Measurement of test-retest variability
Measure: DigiVis test repeatability Time: within 30 days
HPO Nodes
HP:0000646: Amblyopia
Genes 83
TANGO2 TWIST1 LOXL3 GPR143 SMCHD1 CHST3 B3GAT3 COL9A3 ELN KIF11 AP4E1 MLXIPL AFF4 TRIO FGFR2 GDF2 FGFR2 SOBP PHOX2A PIGN WDR26 FGFR3 COX7B FBN1 COL9A2 H1-4 CRYBB1 CRYAA MED25 PIGN PAX6 YME1L1 ZEB1 AP4S1 TUBB3 LYST FGFR2 COL9A1 SCN8A FGFR3 COL4A1 GRHL2 ERF CHN1 VSX1 CBS ARHGEF2 MAFB HCCS SMAD4 NFIX NPHP4 ACVRL1 CHN1 AP4B1 CRYGC ADAMTSL4 WARS2 COL11A1 ENG SALL4 LAMA1 COL11A1 OCRL AP4M1 NDUFB11 TBX1 LAMA1 ADNP WDR26 DPP6 C1QBP PITX2 NR2F1 P4HTM RIC1 LIM2 EPRS1 COL8A2 XYLT2 OGT PUF60 OVOL2 Protein Mutations 0
SNP 0
Primary Outcomes
Description: Measurement bias in logMAR units between DigiVis testing and standard visual acuity testing score compared to
Measure: Comparison of visual acuity measurement using DigiVis testing and standard visual acuity testing Time: within 30 daysDescription: Upper and lower levels of agreement measured in logMAR units
Measure: Levels of Agreement between DigiVis testing and standard visual acuity testing Time: within 30 daysSecondary Outcomes
Description: Measurement of test-retest variability
Measure: DigiVis test repeatability Time: within 30 days